Loading
Cardiac Imaging and Diagnostics / Chemotherapy-induced Cardiotoxicity and Mitigation · Journal article
Cells · August 10, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that summarizes the pathological conditions elevating cardiac troponin in cancer patients and explores molecular mechanisms underlying cardiotoxicity. It identifies current diagnostic challenges and gaps in evidence but does not report original empirical findings or comparative effectiveness data to support practice recommendations.
Journal article. Patients with malignancies at risk of or experiencing cardiac complications.
Cardiac troponin is gaining recognition as a biomarker in cardio-oncology despite elevated levels occurring in numerous clinical scenarios Cancer therapies increase cardiovascular risk, with cardiotoxicity a recognized cause of elevated troponin Malignant tumors may directly impact the myocardium independent of therapy-induced cardiotoxicity
Cancer therapies increase cardiovascular risk, with cardiotoxicity a recognized cause of elevated troponin Malignant tumors may directly impact the myocardium independent of therapy-induced cardiotoxicity
This review identifies unresolved diagnostic challenges in using cardiac troponin to differentiate cardiotoxicity from other causes of myocardial injury in cancer patients. Clinicians should recognize that elevated troponin has multiple etiologies in this population and that current evidence gaps limit specificity of this biomarker.
This is a narrative review that raises questions about cardiac troponin's role in cardio-oncology rather than reporting original research findings or definitive evidence.
This review identifies unresolved diagnostic challenges in using cardiac troponin to differentiate cardiotoxicity from other causes of myocardial injury in cancer patients. Clinicians should recognize that elevated troponin has multiple etiologies in this population and that current evidence gaps limit specificity of this biomarker.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Recent advances in oncological therapies have significantly improved cancer survival rates. However, these therapies have also led to an increased risk of cardiovascular alterations. Cardiac troponin, which is well-known for its role in diagnosing myocardial damage, is gaining recognition as a biomarker in the field of cardio-oncology. Despite its clinical value, differential diagnosis remains challenging, as troponin levels can increase in numerous scenarios, particularly in cardio-oncology. While the most recognized cause is the cardiotoxicity associated with cancer therapy, malignant tumors may also directly impact the myocardium. Furthermore, different cardiac troponins, such as troponins T and I, may have distinct biomarker roles, adding to diagnostic complexity. This review aims to summarize the pathological conditions that cause elevated serum cardiac troponin levels in patients with malignancies. We explore the underlying mechanisms at the molecular and cellular levels and discuss potential clinical applications. We also highlight existing gaps in the current evidence and outline future research directions in this rapidly evolving field.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.